Project Grant R56AI098837

The Flavivirus and Alphavirus REVAMPP (FLARE) Center, funded by a $46,715,173 Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), is developing and optimizing protein nanoparticle, virion-based, and mRNA vaccine platforms, as well as monoclonal antibody-based treatments to rapidly respond to emerging flaviviruses and alphaviruses with pandemic potential. The Center integrates the work of multiple...

Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Trustees of Boston University $808,919 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 18, 2025, to develop novel aglain derivatives as host-targeted antiviral therapeutics against dengue virus (DENV) and other mosquito-borne arboviruses. This R01 Project Grant, which runs through August 31, 2030, addresses a critical public health gap, as dengue ranks among...

Federal Project Grant Award Summary Mapp Biopharmaceutical, Inc. received a $294,583 Project Grant awarded on June 9, 2025, from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel cost-effective multispecific therapeutic for dengue virus infection. The primary deliverable is a tri-specific antibody fragment molecule designed to target two distinct epitopes of the dengue virus envelope...

Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Research Foundation For The State University of New York a $649,530 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 7, 2025, with a completion date of June 30, 2030. This project investigates B cell receptor (BCR)-dependent dengue virus infection as a mechanism underlying immune-mediated enhancement of dengue pathogenesis across all four...

Federal Cooperative Agreement Summary Emory University received a $1.75M Cooperative Agreement from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 22, 2025, with performance extending through July 31, 2030. The award funds a Phase 2B randomized open-label clinical trial assessing dengue virus (DENV) immunity elicited through heterologous prime-boost vaccination combinations using...

This National Science Foundation (NSF) Mathematical and Physical Sciences (CFDA 47.049) project grant award of $1,500,000 supports research by Dr. Tamar Schlick of New York University and Dr. Alain Laederach of the University of North Carolina at Chapel Hill. The project aims to develop advanced computational tools to predict and control how viral protein synthesis is affected by programmed ribosomal frameshifting (PRF) - the mechanism by which viruses and human cells modify gene expression. Key...

The American Type Culture Collection (ATCC) was awarded a $263,771 Project Grant from the Defense Threat Reduction Agency to conduct research titled "Genome-Wide Mapping (GWM) of Host Proteome: Pan Alphavirus Proteome Interactions for Discovery of Broad-Spectrum Countermeasures." The two-year project beginning October 12, 2021 aims to advance fundamental knowledge in scientific research combating weapons of mass destruction, as outlined in the agency's Scientific Research - Combating...

The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $852,121.24 to The Scripps Research Institute-Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of July 22, 2021 through October 31, 2021. The project aims to identify host factors that regulate HIV latency and reactivation in order to develop strategies for durable HIV silencing. The grantee will define the roles of three identified host factors, P32,...

Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $684,921 to the University of Louisville on September 24, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel antiviral therapeutics targeting arthritogenic alphaviruses, particularly Chikungunya virus and related Old World (OW) alphavirus species with pandemic potential. The five-year project, scheduled for completion August 31, 2030, focuses on...

The University of Louisville's Office of Research & Innovation received a $700,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective September 4, 2025, through August 31, 2029. This award funds fundamental biomedical research investigating a novel interaction between alphaviral capsid protein and the host IRAK1 (Interleukin-1 Receptor-Associated Kinase 1) protein. The...